Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
Clinical trial NCT06299371 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06299371
- Sponsor
- Liaoning Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-15
- Primary completion
- 2026-04-15
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.